window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

cryo-electron microscopy

  • Biotech,Drug discovery,Facilities and infrastructure,Research & Development,Technology and platforms

    FairJourney Bio opens cryo-EM facility in San Diego for antibody discovery

    FairJourney Bio has opened a cryo-EM structural biology facility in [...]

    April 17, 2026
  • Biologics & Biosimilars,Biotech,Drug Development,Pharmaceuticals and therapeutics,Technology and platforms

    FairJourney Bio launches cryo-EM services from San Diego laboratories

    FairJourney Bio (FJBio) has expanded its portfolio with the launch [...]

    January 12, 2026
  • Cell & Gene Therapy,Genomics and sequencing,Neurosciences,Research & Development,Technology and platforms

    Atomic ‘Hook’ in motor protein unlocks neuron cargo delivery secrets

    A team from the University of Tokyo and Juntendo University [...]

    November 6, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top